Last 48 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 25.36 | 20.96 | 18.66 | 21.87 | 19.90 | 22.06 | 18.18 | 21.80 | 19.34 | 19.50 | 16.77 | 19.35 | 20.28 | 15.54 | 17.14 | 19.87 | 44.44 | 14.27 | 16.96 | 11.68 | 13.86 |
| — | -5.0% | +2.6% | +0.3% | +2.9% | +13.1% | +8.4% | +12.7% | -4.6% | +25.5% | -2.1% | -2.6% | -54.4% | +9.0% | +1.1% | +70.2% | +220.6% | +57.9% | +155.0% | +25.9% | +95.9% | |
| P/S Ratio | 2.38 | 2.11 | 1.95 | 1.90 | 1.73 | 1.91 | 1.84 | 1.80 | 1.63 | 1.76 | 1.60 | 1.58 | 1.70 | 1.51 | 1.71 | 1.71 | 1.93 | 1.46 | 1.61 | 1.59 | 1.97 |
| — | +10.2% | +6.1% | +5.2% | +6.5% | +8.5% | +14.9% | +14.4% | -4.5% | +16.5% | -6.7% | -8.1% | -11.7% | +3.9% | +6.2% | +8.1% | -2.2% | -11.1% | -1.8% | -0.4% | +44.9% | |
| P/B Ratio | 3.96 | 3.25 | 3.04 | 2.86 | 2.67 | 2.92 | 2.76 | 2.71 | 2.47 | 2.53 | 2.28 | 2.28 | 2.43 | 2.12 | 2.52 | 2.59 | 2.99 | 2.28 | 2.42 | 2.55 | 3.30 |
| — | +11.3% | +9.9% | +5.5% | +7.9% | +15.2% | +21.4% | +19.2% | +1.8% | +19.3% | -9.6% | -12.2% | -18.9% | -6.8% | +3.9% | +1.7% | -9.1% | -18.3% | -12.9% | +1.1% | +39.1% | |
| P/FCF | 20.52 | 11.37 | 17.98 | 33.46 | 15.83 | 12.85 | 11.64 | 24.26 | 12.50 | 17.54 | 14.30 | 74.54 | 8.56 | 34.05 | 11.78 | — | 24.05 | 9.43 | 12.14 | 9.93 | 16.04 |
| — | -11.5% | +54.5% | +37.9% | +26.6% | -26.8% | -18.6% | -67.4% | +46.0% | -48.5% | +21.4% | — | -64.4% | +261.2% | -2.9% | — | +49.9% | -2.0% | +8.9% | +47.8% | +49.0% | |
| EV / EBITDA | 15.01 | 12.62 | 12.19 | 13.07 | 12.10 | 13.01 | 11.34 | 13.12 | 11.81 | 13.05 | 10.67 | 11.89 | 13.47 | 10.30 | 11.34 | 12.40 | 22.21 | 9.21 | 9.94 | 8.28 | 9.90 |
| — | -3.1% | +7.4% | -0.4% | +2.5% | -0.3% | +6.3% | +10.3% | -12.4% | +26.7% | -5.9% | -4.1% | -39.3% | +11.8% | +14.1% | +49.7% | +124.4% | +27.1% | +20.7% | +21.5% | +78.3% | |
| EV / EBIT | 21.66 | 16.56 | 16.65 | 17.97 | 16.17 | 16.97 | 14.55 | 18.32 | 15.78 | 16.77 | 13.95 | 15.70 | 17.90 | 13.72 | 14.65 | 16.27 | 38.44 | 11.87 | 13.62 | 10.49 | 11.76 |
| — | -2.4% | +14.4% | -1.9% | +2.4% | +1.2% | +4.3% | +16.7% | -11.8% | +22.2% | -4.7% | -3.5% | -53.4% | +15.6% | +7.5% | +55.1% | +226.8% | +50.5% | +123.5% | +34.2% | +89.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.9% | 33.6% | 33.7% | 32.5% | 32.6% | 33.7% | 34.2% | 32.5% | 32.7% | 32.6% | 33.5% | 32.6% | 32.3% | 32.9% | 33.9% | 33.1% | 32.5% | 34.9% | 34.3% | 37.0% | 37.4% |
| — | -0.2% | -1.2% | -0.0% | -0.5% | +3.4% | +1.8% | -0.1% | +1.2% | -0.8% | -1.0% | -1.5% | -0.5% | -5.9% | -1.3% | -10.5% | -13.1% | -12.3% | -11.1% | -8.1% | -11.5% | |
| Operating Margin | 14.5% | 15.5% | 15.1% | 13.8% | 13.9% | 13.7% | 15.9% | 13.0% | 13.8% | 13.3% | 14.8% | 12.7% | 11.7% | 14.9% | 14.9% | 13.1% | 5.8% | 15.8% | 15.8% | 19.6% | 19.5% |
| — | +12.8% | -4.9% | +5.6% | +1.2% | +3.3% | +7.1% | +2.9% | +18.0% | -11.0% | -0.5% | -3.1% | +101.7% | -5.5% | -5.9% | -33.4% | -70.4% | -32.9% | -24.3% | -19.0% | -26.2% | |
| Net Margin | 9.0% | 10.1% | 10.5% | 8.7% | 8.7% | 8.7% | 10.2% | 8.3% | 8.5% | 9.1% | 9.6% | 8.2% | 8.4% | 9.8% | 10.1% | 8.7% | 4.3% | 10.2% | 9.5% | 13.6% | 14.2% |
| — | +15.8% | +3.0% | +4.9% | +3.1% | -4.2% | +6.9% | +1.2% | +0.9% | -7.3% | -5.0% | -5.4% | +93.8% | -4.0% | +5.8% | -36.1% | -69.5% | -43.7% | -61.4% | -21.2% | -26.1% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.0% | 3.9% | 4.1% | 3.4% | 3.3% | 3.3% | 3.9% | 3.2% | 3.2% | 3.3% | 3.4% | 3.0% | 3.0% | 3.5% | 3.8% | 3.3% | 1.6% | 3.9% | 3.6% | 5.4% | 6.0% |
| — | +18.3% | +5.4% | +6.8% | +4.0% | +0.6% | +13.7% | +5.5% | +8.4% | -5.1% | -8.1% | -9.8% | +81.3% | -11.6% | +4.8% | -38.8% | -72.5% | -50.9% | -63.3% | -20.3% | -30.7% | |
| ROA | 6.1% | 1.8% | 1.9% | 1.5% | 1.5% | 1.5% | 1.8% | 1.4% | 1.4% | 1.5% | 1.6% | 1.4% | 1.4% | 1.7% | 1.8% | 1.6% | 0.8% | 1.9% | 1.7% | 2.6% | 2.9% |
| — | +19.9% | +7.2% | +11.2% | +9.8% | +1.0% | +7.9% | -0.7% | -1.4% | -9.8% | -8.2% | -12.0% | +80.1% | -12.6% | +2.9% | -39.8% | -72.9% | -49.7% | -62.8% | -21.8% | -30.0% | |
| ROIC | 8.8% | 2.7% | 2.5% | 2.1% | 2.2% | 2.2% | 2.4% | 1.9% | 2.1% | 2.0% | 2.3% | 2.0% | 1.8% | 2.3% | 2.4% | 2.2% | 1.0% | 2.8% | 2.8% | 3.7% | 3.9% |
| — | +22.5% | +1.1% | +9.8% | +5.5% | +8.0% | +5.6% | -2.7% | +14.8% | -12.0% | -3.2% | -8.6% | +81.8% | -19.9% | -14.4% | -40.9% | -74.9% | -41.0% | -28.6% | -22.7% | -32.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.95 | 0.78 | 0.82 | 0.91 | 0.95 | 0.87 | 0.87 | 0.93 | 1.00 | 1.01 | 0.76 | 0.82 | 0.84 | 0.75 | 0.78 | 0.75 | 0.77 | 0.73 | 0.71 | 0.72 | 0.71 |
| — | -9.6% | -6.1% | -2.4% | -5.4% | -14.1% | +15.0% | +14.1% | +20.0% | +34.1% | -3.1% | +9.1% | +8.7% | +2.8% | +9.7% | +4.4% | +8.4% | +2.3% | -8.0% | +5.8% | +5.1% | |
| Debt / EBITDA | 3.18 | 10.04 | 10.55 | 12.78 | 12.91 | 12.09 | 10.99 | 13.52 | 13.96 | 15.32 | 10.78 | 12.87 | 14.28 | 10.84 | 10.78 | 11.22 | 18.41 | 9.28 | 9.37 | 7.53 | 7.25 |
| — | -16.9% | -4.0% | -5.4% | -7.5% | -21.1% | +1.9% | +5.1% | -2.2% | +41.3% | -0.0% | +14.7% | -22.5% | +16.8% | +15.1% | +48.9% | +153.9% | +50.3% | +27.6% | +23.0% | +39.2% | |
| Current Ratio | 1.04 | 1.70 | 1.59 | 1.18 | 1.04 | 1.13 | 1.09 | 1.44 | 1.10 | 1.25 | 1.00 | 0.97 | 1.31 | 1.12 | 0.92 | 1.34 | 1.22 | 1.46 | 1.54 | 1.46 | 1.56 |
| — | +50.7% | +46.5% | -18.1% | -5.3% | -10.0% | +8.3% | +48.5% | -15.6% | +11.8% | +8.5% | -27.6% | +6.8% | -23.0% | -39.9% | -8.0% | -21.7% | -10.2% | +11.2% | -17.1% | -9.2% | |
| Quick Ratio | 0.96 | 1.58 | 1.46 | 1.08 | 0.96 | 1.04 | 0.99 | 1.31 | 1.02 | 1.17 | 0.91 | 0.89 | 1.20 | 1.01 | 0.83 | 1.20 | 1.10 | 1.34 | 1.42 | 1.34 | 1.44 |
| — | +51.9% | +47.0% | -17.8% | -5.4% | -10.7% | +8.9% | +46.9% | -15.5% | +15.7% | +10.4% | -25.7% | +9.3% | -24.9% | -41.8% | -10.6% | -23.9% | -10.8% | +13.1% | -17.6% | -9.5% | |
| Interest Coverage | 5.86 | 7.82 | 7.03 | 6.30 | 5.99 | 5.87 | 6.57 | 4.83 | 5.15 | 6.10 | 7.68 | 6.43 | 6.15 | 8.29 | 9.13 | 8.49 | 4.03 | 10.49 | 9.50 | 13.22 | 14.21 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DGX stock.
Quest Diagnostics Incorporated's current P/E is 25.4x. The average P/E over the last 4 quarters is 20.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quest Diagnostics Incorporated's current operating margin is 14.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Quest Diagnostics Incorporated's business trajectory between earnings reports.